Dilated
cardiomyopathy is a condition strongly related to heart attacks, in
which the ventricles are enlarged, resulting in a thinning of cardiac
walls, and insufficient pumping of blood. Dilated cardiomyopathy can
occur at any age, though it is most common in the 20-40 demographic.
One of the major reasons of dilated cardiomyopathy is genetic. Some
other factors that can cause dilated cardiomyopathy are thyroid
disorders, viral infections of the heart, diabetes, alcoholism, and
heart valve malformations.
Browse
Full Global Dilated Cardiomyopathy Therapeutics Market Report With
Complete TOC @
http://www.transparencymarketresearch.com/dilated-cardiomyopathy-market.html
Angiotensin
II Receptor Blockers Held Largest Share of Dilated Cardiomyopathy
Therapeutics Market in 2013 by Revenue
The
dilated cardiomyopathy therapeutics market worldwide is segregated on
the basis of drug class, pipeline drugs, and geography. The dilated
cardiomyopathy therapeutics market globally in terms of drug class is
broadly classified as angiotensin-converting enzyme (ACE) inhibitors,
beta blockers, aldosterone antagonists, and angiotensin II receptor
blockers (ARBs). Of all the drug class, angiotensin II receptor
blockers held the largest share of the dilated cardiomyopathy
therapeutics market in 2013 by revenue, followed by beta blockers.
The
high demand for the leading drugs for the treatment of dilated
cardiomyopathy from developed regions such as Europe and North
America is a reason for the large market shares of these classes of
drugs. When used in combination either with ACE or ARBs, aldesterone
antagonist drugs have proven to have a positive impact on the
reduction of progressive conditions such as Duchenne muscular
dystrophy (DMD).
The
global dilated cardiomyopathy therapeutics market was worth US$651.0
million in 2013. By 2020, the global dilated cardiomyopathy
therapeutics market is projected to be worth US$328.6 million which
shows a decline of 7% CAGR from 2014 to 2020.
Clinical
Trials May Halt Expected Reduction of Dilated Cardiomyopathy
Therapeutics Market
The
dilated cardiomyopathy therapeutics market worldwide is driven by
growing incidence of congestive heart failure which is significantly
related with DCM. On a global scenario, dilated cardiomyopathy is
associated to 30% to 40% for congestive heart failure cases every
year. Due to the growing incidence of congestive heart failure
worldwide, several companies have initiated clinical trials for the
advancement of therapeutics for dilated cardiomyopathy.
Some
of the clinical trials undertaken are a phase II study by Array
BioPharma in 2015 for its drug class ARRY-371797, a phase II study by
Celladon Corporation in 2014 for its drug class MYDICAR. The dilated
cardiomyopathy therapeutics market is expected to get a boost on the
successful completion of these clinical trials. However, implantable
devices such as heart pumps, pacemakers, and advancement in gene
therapy will restrain the growth of dilated cardiomyopathy
therapeutics market.
Browse
Full Press Release Report :
North
America Leads Global Dilated Cardiomyopathy Therapeutics Market
According
to geographical segmentation, the dilated cardiomyopathy therapeutics
market is divided into four regions, which are Asia Pacific, Europe,
North America, and Rest of the World (RoW). North America held the
largest share of the dilated cardiomyopathy therapeutics market in
2013 owing to rising cases of heart diseases and acceptance for
branded drugs.
The
U.S. and Canada make up the dilated cardiomyopathy therapeutics
market in North America. The prevalence of DCM in the U.S. is high;
5-8 people out of every 100,000 are diagnosed with DCM. In Canada,
heart failure accounts for 9% of total deaths in the country, which
is driving the dilated cardiomyopathy therapeutics market in North
America.
In
Europe, countries such as Spain, Germany, the U.K., and Italy
contribute significantly towards the growth of the dilated
cardiomyopathy therapeutics market. The dilated cardiomyopathy
therapeutics market is growing in Asia Pacific and Rest of the World
(RoW) owing to rising economic power, higher incomes, and growing
demand for generic drugs.
Some
of the key players in the dilated cardiomyopathy therapeutics market
are Teva Pharmaceutical Industries Ltd , Merck & Co., Inc., Array
BioPharma, Inc., Celladon Corporation, GlaxoSmithKline plc, Pfizer,
Inc., Janssen Pharmaceuticals, Inc., Novartis International AG,
Sanofi S.A., AstraZeneca plc and Vericel Corporation.
Request a Brochure of this Report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=2293
About
Us
Transparency
Market Research is a global market intelligence company, providing
global business information reports and services. Our exclusive blend
of quantitative forecasting and trends analysis provides
forward-looking insight for thousands of decision makers. Our
experienced team of Analysts, Researchers, and Consultants, use
proprietary data sources and various tools and techniques to gather,
and analyze information.
Our
data repository is continuously updated and revised by a team of
research experts, so that it always reflects the latest trends and
information. With a broad research and analysis capability,
Transparency Market Research employs rigorous primary and secondary
research techniques in developing distinctive data sets and research
material for business reports.
Contact
Mr.
Nachiket
State
Tower,
90
State Street,
Suite
700,
Albany
NY - 12207
United
States
Tel:
+1-518-618-1030
USA
- Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
http://www.transparencymarketresearch.com
